Abstract
This study compares the toxic effects of native cyclosporin A (CyA) with those of targeted CyA that is conjugated with the anti-rat-thymocyte antibody of rabbit originvia the N-(2-hydroxypropyl)methacrylamide (HPMA) carrier bearing digestible, reactive oligopeptide side chains. Ten toxic doses of native CyA (50 mg/kg i.p.) given to young adult rats in the course of 14 d produced a severe renal lesion—diffuse microvacuolization of the proximal tubules in the deep cortex, and hypergranulation of juxtaglomerular regions. Severe atrophy of the thymic medulla was documented by morphometry. In the cortex the epithelial reticular (but not deep interdigitating) cells showed ultrastructural signs of severe degeneration and lysis. The immature CD4+8+ double-positive cortical lymphocytes were preserved whereas, the single-positive medullary thymocytes were greatly depleted; there was also a restriction of MHC class II antigen expression in the medulla. The number of medullary B cells was increased. The cytokeratin net was focally shrunken in the cortex and almost negative in the medulla, with loss of Hassall's corpuscles. After ten corresponding doses of antibody-targeted conjugated CyA no damage to the renal tubules and arterioles appeared and the antiGBM or immune-complex deposition was absent. The thymus had a normal medulla with numerous mature thymocytes and the cortical epithelial reticulum remained well preserved. Thus, the main toxic effects of CyA could be eliminated by targeting. The T-cell-targeted drug was tested for preserved immunosuppressive properties and non-toxic character of HPMA copolymer carrier.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antonovych T.T., Sabnis S.G., Austin H.A., Palestine A.G., Balow J.E., Nussenblatt R.B., Helfrich G.B., Foegh M.L., Alijani M.R.: Cyclosporin A-induced arteriolopathy.Transplant. Proc.20, 951–958 (1988).
Bach J.F., Chatenoud L.: Immunologic monitoring of Orthoclone OKT 3-treated patients—the problem of antimonoclonal immune response.Transplant. Proc.19, 17–20 (1987).
Baumann G.: Molecular mechanisms of immunosuppressive agents.Transplant. Proc.24, 4–7 (1992).
Belnap L.G.P., Hammond E.H., Yowell R., Richards K.F., Rees W.V., Stevens L.E.: Baseline biopsies define cyclosporine nephrotoxicity.Transplant. Proc.21, 1485–1486 (1989).
Bechorner W.E., Namnoun J.D., Hess A.D., Shinn C.A., Santos G.W.: Cyclosporin A and the thymus.Amer. J. Pathol.126, 487–496 (1987).
Blair J.T., Thomson A.W., Whiting P.H., Davidson R.J.L., Simpson J.G.: Toxicity of the immune suppressant cyclosporin A in the rat.J. Pathol.138, 163–178 (1982).
Borel J.F.: The cyclosporins.Transplant. Proc.21, 810–815 (1989).
Brayman K.L., Hickey W.F., Barker C.F., Naji A.: Thymic major histocompatibility complex antigen expression and suppressor cell sparing by cyclosporine.Transplant. Proc.19, 1181–1183 (1987).
Brodehl J., Offner G., Hoyer P.F., Schirg E., Pichlmayr R., Wonigeit K.: Cyclosporin A in pediatric kidney transplantation and its effects on posttransplantation growth.Nephron44, 26–31 (1986).
Curtis J.J., Laskow D.A.: Cyclosporine-induced nephrotoxicity—pathophysiology of decreased renal flow.Transplant. Proc.20, 540–543 (1988).
Duijvestijn A.M., Köhler Y.G., Hoefsmit E.C.M.: Interdigitating cells and macrophages in the acute involuting rat thymus.Cell Tissue Res.224, 291–301 (1982).
Farland E.J.M.C., Scearce R.M., Haynes B.F.: The human thymic microenvironment.J. Immunol.133, 1241–1249 (1984).
Flanagan P.A., Duncan R., Říhová B., Ŝubr V., Kopeĉek J.: Immunogenicity of protein-N-HPMA copolymer conjugates in A/J and B 10 mice.J. Bioact. Compat. Polymers5, 151–166 (1990).
Goldstein G.: Overview of Orthoclone OKT 3—monoclonal antibody for therapeutic use in transplantation.Transplant. Proc.19, 1–6 (1987).
Hamilos D.L.: Immunocompetent dendritic cells, pp. 89–118 in J.M. Cruse, L.R. Lewis (Eds).The Year in Immunology, Vol. 3, Karger, Basel 1988.
Haynes B.F., Scearce R.M., Lobach D.F., Hensley L.L.: Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment.J. Exp. Med.159, 1149–1168 (1984).
Jegorov A., Říhová B., Ulbrich K., Maťha V., Strohalm J., Fornůsek L.: Targeted polymeric conjugates of cyclosporin.Czechosl. Patent Appl. PV 215–91 (1991).
Jenkins M.K., Schwartz R.H., Pardoll D.M.: Effects of cyclosporin A on T cell development and clonal deletion.Science241, 1655–1658 (1988).
Julius M.H., Simpson E., Herzenberg L.A.: A, rapid method for the isolation of functional thymus-derived murine lymphocytes.Eur. J. Immunol.3, 645–649 (1973).
Kopeček J.: Biodegradation of biomedical polymers, pp. 305–320 in H. Benoit, M. Rempp (Eds):IUPAC Macromolecules Pergamon Press, oxford 1982.
Kreis H., Chkoff N., Chatenoud L., Campos H., Bach J.F., Goldstein G.: Prolonged administration of Orthoclone OKT 3 to kidney allograft recipients.Transplant. Proc.18, 954–956 (1986).
Levey R.H., Medawar P.B.: Some experiments on the action of antilymphoid sera.Proc. N.Y. Acad. Sci.120, 164–177 (1966).
Löning T., Caselitz J., Otto H.F.: The epithelial framework of the thymus in normal and pathologic conditions.Virchows Arch. A Pathol. Anat.392, 7–20 (1981).
Mayes J.T., Thistlethwaite J.R., Stuart J.K., Buckingham M.R., Stuart F.P.: Reexposure to OKT 3 in renal allograft recipients.Trasplantation45, 349–353 (1988).
Mihatsch M.J.: Selectivity still has its price—personal experience with cyclosporine over the last 10 years.Transplant. Proc.24, 67–70 (1992).
Mihatsch M.J., Thiel G., Ryffel B.: Histopathology of cyclosporine nephrotoxicity.Transplant. Proc.20, suppl. 759–771 (1988).
Myers B.D., Newton L., Boshkos C., Macoviak J.A., Frist W.H., Derby G.C., Perlroth M.G., Sibley R.K.: Chronic injury of human renal, microvessels with low-dose cyclosporine therapy.Transplantation46, 694–703 (1988).
Myers B.D., Newton L., Oyer P.: The case against the indefinite use of cyclosporine.Transplant. Proc.23, 41–42 (1991).
Myers B.D., Ross J., Newton L., Loetscher L., Perlroth M.: Cyclosporine-associated chronic nephropathy.New Engl. J. Med.311 699–705 (1984).
Naquet P., Lepesant H.: The role of accessory cells in positive and negative selection in the thymus. pp. 63–104 in L. Fornůsek, V. Vêtviĉka (Eds.),Immune System Accessory Cells CRC Press, Boca Raton 1992.
Prud'Homme G.J., Vanier L.E.: Cyclosporine tolerance and autoimmunity.Clin. Immunol. Immunopathol.66, 185–192 (1993).
Říhová B., Jegorov A., Strohalm J., Matha V., Rossmann P., Fornůsek L., Ulbrich K.: Antibody-targeted cyclosporin A.J. Control. Release19, 25–40 (1992).
Říhová B., Kopeĉek J.: Biological properties of targetable HPMA-antibody conjugates.J. Control. Release2, 289–310 (1985).
Říhová B., Kopeĉková P., Strohalm J., Rossmann P., Vêtviĉka V., Kopeĉek J.: Antibody-directed affinity therapy applied to the immune system.Clin. Immunol. Immunopathol.46, 100–114 (1988).
Říhová B., Strohalm J., Plocová D., Ulbrich K.: Selectivity of antibody-targeted anthracycline antibiotics on T lymphocytes.J. Bioact. Compat. Polymers5, 249–266 (1990).
Říhová B., Ulbrich K., Vêtviĉka V., Bilej M., Duncan R., Kopeĉek J.: Histocompatibility of HPMA copolymers containing adriamycin.Biomaterials10, 335–342 (1989).
Rossmann P., Jirka J., Chadimová M., Reneltová I., Saudek F.: Arteriolosclerosis of the human renal allograft—morphology, origin, life history and relationship to cyclosporine therapy.Virchows Arch. A Pathol. Anat.418, 129–141 (1991).
Rossmann P., Říha I., Matouŝovic K., Bohdanecká M., Bukovský A.: Experimental ablation nephropathy—fine structure, morphometry, cell membrane epitopes, glomerular polyanion, and effect of subsequent transplantation.Path. Res. Pract.186, 491–506 (1990).
Ryffel B.: Ciclosporin toxicology—experimental studies, pp. 181–187 in J.F. Borel (Ed):Ciclosporin. Karger, Basel 1986.
Ryffel B., Hiestand P., Foxwell B., Donatsch P., Boelsterli H.J., Maurer G., Mihatsch M.J.: Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats.Transplant. Proc.18, 41–45 (1986).
Salomon D.R.: An alternative view mimicking the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosuppression for long-term kidney transplant recipients.Transplant. Proc.23, 2115–2116 (1991).
Thomson A.W., Whiting P.M., Blair J.T., Davidson R.J.L., Simpson G.J.: Pathological changes in the rat during a 3-week course of high dosage cyclosporin A.Transplantation32, 271–277 (1981).
Volfová I., Říhová B., Vêtviĉka V., Rossmann P., Ulbrich K.: Biocompatibility of biopolymers.J. Bioact. Compat. Polymers7, 175–190 (1992).
Wilson C.B., Dixon F.J., Fortner J.G., Cerilli G.J.: GBM-reactive antibody in antilymphocyte globulin.J. Clin. Invest.50, 1525–1535 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rossmann, P., Říhová, B., Strohalm, J. et al. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (Reduced toxicity of targeted drug). Folia Microbiol 42, 277–287 (1997). https://doi.org/10.1007/BF02819003
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02819003